Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
Financial health
Theravance Biopharma, Inc. financial health
Start with the overall verdict and the rule-based risk checks for TBPH, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.
Cash & Investments
$395.50M
Debt Cushion
$322.20M
Current Ratio
13.1x
Interest Coverage
Not available
Risk checks
1 of 11 checks flagged
Interest coverage
0.0×
Passes when: Operating income is at least 1.5 times interest expense.
Positive equity
Positive
Passes when: Shareholders’ equity is above zero.
Short-term liquidity
13.1×
Passes when: Current assets are at least 1 times current liabilities.
Near-term debt coverage
36.7×
Passes when: Cash and short-term investments cover debt due within 12 months.
Manageable net debt
Net cash
Passes when: Net debt is below 3 times EBITDA.
Debt repayment from cash flow
0.3 yr
Passes when: Free cash flow could repay all debt within 5 years.
Debt growth versus revenue growth
13.1% vs. 27.9%
Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.
Tangible equity base
0.0%
Passes when: Goodwill and intangibles are below 50% of equity.
Altman Z-score trend
-2.09 → 1.58
Passes when: The Z-score is stable or rising, or stays above 2.99.
Stock-based compensation
6.7%
Passes when: Stock-based compensation is no more than 20% of operating cash flow.
Share dilution
-3.7% per year
Passes when: Diluted share count grows no more than 2% per year.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
No financial scores available.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | 4 | 1 | 4 | 2 | 2 | 2 | 5 | 5 | 5 | 7 |
| Altman Z | 1.88 | -0.90 | -1.54 | -4.10 | -4.95 | -7.31 | 1.25 | -1.12 | -2.09 | 1.58 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$288.10M
Q1 2026
Quick Ratio
13.1x
Q1 2026
Current Ratio
13.1x
Q1 2026
Cash Ratio
9.1x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q1 2026)
$385.86M
Current assets − current liabilities
Days sales outstanding
324 d
-64 days vs. prior year
Days inventory outstanding
0 d
+0 days vs. prior year
Days payables outstanding
170 d
+148 days vs. prior year
Cash conversion cycle
155 d
-212 days vs. prior year
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$73.30M
Q1 2026
Debt/Equity
0.3x
Q1 2026
Debt/Assets
0.2x
Q1 2026
Interest Coverage
—
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
Net cash: $321.37M
Total debt − cash − short-term investments
Net debt / EBITDA
Net cash
Above 3× is elevated
Free cash flow / debt
366.6%
Share of debt one year of FCF could repay
Years to repay debt
0.3 yr
Total debt ÷ free cash flow
Operating cash flow / current liabilities
8.5×
Above 1× funds a year of obligations
Interest coverage
0.0×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 36.7×.
Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$836,000.00
Q1 2026
Assets
$472.31M
Q1 2026
Liabilities
$181.72M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
Claims on $472.31M in assets
- Payables0.2%
- Short-term debt2.3%
- Long-term debt6.9%
- Other liabilities29.0%
- Equity61.5%
Goodwill + intangibles
$0
0.0% of total assets
Share of equity
0.0%
Above 50% leaves little tangible backing
Tangible equity
$290.59M
Equity left after writing off goodwill and intangibles
Deferred revenue
$0
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does Theravance Biopharma, Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
Vir Biotechnology, Inc. VIR:NASDAQ | $1.80B | 0.24 | 0.19 | 0.11 | — | 5.54 | 5.54 | 2.52 |
ArriVent BioPharma, Inc. AVBP:NASDAQ | $1.33B | 0.00 | 0.00 | 0.27 | — | 12.83 | 12.83 | 1.76 |
Tyra Biosciences, Inc. TYRA:NASDAQ | $1.30B | 0.02 | 0.02 | 0.60 | — | 14.67 | 14.67 | 4.28 |
Replimune Group, Inc. REPL:NASDAQ | $1.04B | 0.18 | 0.14 | 0.14 | — | 7.95 | 7.95 | 1.78 |
Monte Rosa Therapeutics, Inc. GLUE:NASDAQ | $994.32M | 0.17 | 0.09 | 2.89 | — | 6.12 | 6.12 | 2.02 |
Geron Corporation GERN:NASDAQ | $808.32M | 1.11 | 0.44 | Net cash | — | 4.66 | 4.66 | 0.71 |
Valneva SE VALN:NASDAQ | $582.22M | 1.95 | 0.52 | Net cash | — | 1.85 | 2.38 | 1.17 |
LENZ Therapeutics, Inc. LENZ:NASDAQ | $122.75M | 0.00 | 0.00 | 0.30 | — | 13.80 | 13.80 | 1.19 |
Questions
Financial health questions
Common questions about TBPH's balance sheet, answered from the reported figures.
Is TBPH's balance sheet healthy?
Theravance Biopharma, Inc. (TBPH) has a current ratio of 13.14, a quick read on short-term liquidity.
How leveraged is TBPH?
Debt to equity is 0.25, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.